Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If so, then this might be game over and millions of shares will hit the market. I do not think the registration of Pepin's shares has anything to do with the strategy. Every investor would want to have his holdings registered at one point. Some might sell now on frustration that Oxycyte is not playing a major part in the companies strategy, (as it appears from todays call). Patient enrollment in phase 3 might give a boost and if results and good data will follow the stock price has a great potential from here...
put position has been rolled to Aug (16) expiry date (overall puts have increased , still pressure the stock price, those speculators do not believe in the possibility that the company finally might deliver, GLTA….
View options by expirationLayout: Stacked | Straddle
July
Calls
Strike Price Change Bid Ask Volume Open Int
2.50 2.40 0.00 1.10 1.80 - 0
5.00 0.20 0.00 - 0.05 - 226
7.50 - - - 0.45 - 0
10.00 - - - - - 0
Puts
Strike Price Change Bid Ask Volume Open Int
2.50 - - - 0.45 - 0
5.00 1.10 0.00 0.70 1.40 - 7
7.50 3.50 0.00 3.00 4.20 - 3995
10.00 - - - - - 0
August 16,
Calls
Strike Price Change Bid Ask Volume Open Int
2.50 - - 1.05 1.90 - 0
5.00 0.10 0.00 - 0.15 - 762
7.50 0.05 0.00 - 0.05 - 215
10.00 0.20 0.00 - 0.45 - 83
Puts
Strike Price Change Bid Ask Volume Open Int
2.50 - - - 0.50 - 0
5.00 1.25 0.00 0.80 1.65 - 723
7.50 3.50 0.00 2.95 4.30 - 8152
10.00 5.90 0.00 5.10 7.10 - 17
good observation. If it is a sell to close that speculator made a few hundred thousand profit on that position, overall a positive sign. Patient enrollment phase 3 most likely starts in the next few weeks, GLTA
Recent Scientific Publications Highlight Potential Benefits of Levosimendan in Cardiac Surgery and Additional Critical Care Conditions
Publications review potential benefits of levosimendan in various critical care conditions including: cardiac surgery, cardiogenic shock, septic shock, acute renal failure
http://finance.yahoo.com/news/recent-scientific-publications-highlight-potential-123000929.html
8:30 am Oxygen Biotherapeutics: recent scientific publications highlight potential benefits of Levosimendan in cardiac surgery and additional critical care conditions (OXBT) : Co highlighted three recent review articles examining the current clinical use of levosimendan and its potential to address a wide range of critical care conditions. Oxygen is currently preparing to initiate a Phase 3 trial in the United States during the third quarter to evaluate levosimendan in cardiac surgery patients at risk of developing low cardiac output syndrome.
Summaries of the review articles are as follows:
Levosimendan: points to "a range of beneficial haemodynamic and cardio protective effects, and a favourable influence on clinical outcomes." The article also points to preliminary positive observations in additional conditions that require inotropic support -- such as right ventricular failure, cardiogenic shock, septic shock, and Takotsubo cardiomyopathy.
Preoperative Levosimendan: The authors highlight that "through this triple mechanism, levosimendan increases the contractile force of the cardiac muscle fibers, cause both peripheral arterial and venous vasodilation, and exerts a cardio protective effect against ischemia.
your post is not only overly pessimistic , it is based on pure frustration and destructive nature. Levo and Oxycyte are 2 potential products, clinical trials started and Oxycyte will most likely continue in the US soon. Levo has FDA fast track approval phase 3 which will start this summer, (best sites selected and announced) this is not fantasy but believe what you want to believe, it is basically not worth replying to certain comments - "a dead dog is not worth to be carried over the road- it is still dead on the other side", some people will never change their opinion, so what…just wait and see…time will tell...
if and when ---- this stock will be well over 30, valuation of over 1 Billion is not unrealistic with a licensed product with a few billion in revenues and this company has to 2 main products in the pipeline, again if and when but this time i believe mistakes from the past will not be repeated and management will deliver. next stop is $15 with the usual ups and downs but when established this will move strong towards $25 and over, GLTA.
open int PUT strike 7.5 - July date : 8000! massive manipulation GLTA. This trade could be profitable as OBI mentioned patient enrollment this summer, not likely before July 19, so shorts will make money as this stock (investor base and management- the later no actual proof delivered yet) is still weak. A massive rebound is expected after the option exp. date with the news of phase 3 having started. This stock is a buy, company is funded for years and no bad news in sight for months. This is certainly a strong buy.
Good to see that institutional and professional investors believe in OXBT.
Filing sc 13G ; Broadfin Capital LLC increases their holdings by about 500'000 shares compared to the last filing. Their holdings now over 5%, I bet they know what they are doing. Interesting to see what trick the shorts want to pull out of the hat next. time is running good luck to all shorts….
coincidence?! somebody bought 2500 PUT options (long) strike 7.5 , price 3, exp. July, worth 750k , very outstanding and unusual option trade -! only in profit when oxbt pps is below 4.5 on July option date! - and suddenly this report appears. SEC should check up on this - short position trying to manipulate as it gets close to patient enrollment and positive momentum. btw every single investor would want to have his holdings registered at one point and as this one has to report when selling everybody can see if he really is loading off , i doubt it. Somebody is really scared here to take such drastic action, (irregular put option volume in combination with such report) should be even more scared now as this could potentially result in a SEC investigation.
such an I…., the SEC would most likely not allow any information to be kept secretly if it would have influence on the stock price, just common sense …and most likely one of OXBT partner companies requested the "cto" in order to keep some trade secret in regards to formula or price….happy easter
- Levosimendan is an approved drug in around 55 countries worldwide.
- Duke University’s Duke Clinical Research Institute, (DCRI) to conduct the Phase 3 trial of the Company’s newly acquired compound, levosimendan
- The United States Food and Drug Administration (FDA) has granted Fast Track status for levosimendan
- OXBT has been notified recently by the U.S. Food and Drug Administration (the “FDA”) that the agency has completed its review of the September 2013 nonclinical submission and has lifted the clinical hold on Oxycyte®.
- ongoing clinical trial in traumatic brain injury (TBI) is a double-blind, placebo–controlled, dose-escalation study.
- the Company received net proceeds of approximately $55.0 million
- New Management - new company guidance - Oxygen Biotherapeutics Closes the Acquisition of Phyxius Pharma Assets Related to Levosimendan; John Kelley Appointed CEO of Oxygen Biotherapeutics
Past is past and the future is bright, for everyone his own opinion but somebody would say all the above are lies and fluffy grams.
Time will tell and some will be right and some will be wrong.
what are you going to write when money is in the bank?
Oxygen Biotherapeutics (OXBT) Surges Over 59% As New Pfizer (PFE) Partnership Deal Gets Lined Up Ventures Sierra World Equity Review
HEADLINE: Oxygen Biotherapeutics (OXBT) Surges Over 59% As New Pfizer (PFE) Partnership Deal Gets Lined Up Ventures Sierra World Equity Review.
Oxygen Biotherapeutics And Pfizer Partnership Deal
Sierra's leads indicate that big pharma Pfizer is about to enter into a partnership with Oxygen Biotherapeutics, on Monday both stocks were higher with Oxygen Biotherapeutics gaining over 59% on positive progress in discussions with Pfizer projects Sierra.
I believe as soon as there is confirmed good data from various tests and preferably a license deal with a well know company, one can expect that investors (possibly institutionals, with the needed funding in place) will buy the stock as the potential of this technology will start to unfold. At this moment I do not believe that the real potential of this company/product is in the price. Current price is more reflecting a failure with little hope. If this technology works and the product shows efficacy this is a multi hundred million dollar company. This stock will stay volatile but the result will be flop or top, zero or over 10$, hoping for the later.
You are spot on ! Who is constantly accumulating this stock ?
sellers - probably investment fund, some short term traders, frustrated retail investors in US and EU
buyers - probably little short covering, little buying from short term traders and ????
This is the big question mark. There is no real reason to buy this stock. No real news, nobody out in the open market really knows what is going on and if the road map set out by the company will be achieved. It is known that data from dermatology test should be coming in a few month time, that pre-clinical trials in stroke are on the way, that the Navy is testing for DCS and the Army funding some test in TBI of which the results , if positive, should lift the clinical hold from FDA, the monthly burn rate is reduced but this alone is still no reason to buy a big position in this stock , unless you have loads of gambling money to risk. The group, person or fund accumulating this stock must really know what they are doing. Nobody is buying and accumulating an "illiquid" stock , (with such a history and track record) a rather large position over time on various levels (as it looks like), without having a master plan at hand. The way of accumulating the position is very professional.
This stock is in for a potentially very positive surprise over time.
Bluebang you have a valid point.
A clear "no" in the proxy regarding by law change(staggered board)
A "yes" for all other points hoping that spending and burn rate will be cut dramatically and some compensation will be made with restricted shares, as only then they start to care about the stock price, it needs to hurt their own pockets. I wish Vatea will take control and put a top board and a new CEO in place soon. At this point Vatea investors have lost over $10 Million, and i think it is in their own best interest to get this company back on track. We all fully agree that there should not be any attendance fee for board meetings. We will soon see in which direction this ship will sail.
page 31, proxy...Employment of Maria Tamargo
Maria Tamargo is the daughter-in-law of Mr. Stern, our former Chief Executive Officer, and we employed her as our Senior Vice President of Dermacyte Development. In this capacity she received an annual salary of $120,000, milestone triggered bonuses with a total potential of $30,000, a monthly auto allowance of $500 and 1,000 options annually. Effective August 24, 2011, Ms. Tamargo is no longer employed with us.
well posted, buys around this level increase. It tested the years low and forms a bottom.
Every buyer here might be in for a big ticket.
The bashers had their joy with this diving stock price, hopefully they made some money because now it is time "to be long", veeeeeery long.....
Spot on, fully agree! But there is more. Many people who try the skin product love it, it works. The technology is unique and patented , the intravenous indications (TBI & others) are still alive, the potential huge, Pentagon involved, main Investors still commited,but for how long? Oxbt is a take over candidate. The longer the share price is going down, the easier it will be to buy the company at a low price because frustration is mounting. It looks like there is a plan.
Spot on, fully agree! But there is more. Many people who try the skin product love it, it works. The technology is unique and patented , the intravenous indications (TBI & others) are still alive, the potential huge, Pentagon involved, Investors still commited,but for how long? Oxbt is a take over candidate. The longer the share price is going down, the easier it will be to buy the company at a low price because frustration is mounting. It looks like there is a plan.
Dermacyte Switzerland Ltd. is an independent company, Oxygen Biotherapeutics INC has no ownership, this according an overseas source. This company will distribute not only concentrate & eye complex from Dermacyte but all future cosmetic products from its line. Additional sales can not harm the company's income, which is not great yet...
Military Interest in Oxycyte Continues
Jason Napodano, CFA, On Monday September 20, 2010, 10:03 am EDT
Military interest in Oxygen Biotherapeutics’ (NasdaqCM: OXBT) Oxycyte continues to be a strong driver for clinical development. The company’s phase 2b clinical trial studying Oxycyte for the treatment of traumatic brain injury (TBI), which has been enrolling at sites in Switzerland and Israel, has recently been expanded to include enrollment from the Israeli military.
We believe this could work to greatly enhance enrollment, as military blast injury (MBI) is a significant cause of TBI. For example, there were an estimated 380k such incidences among American military personnel from 2002-2008. TBI is the largest killer in the War on Terror, and primarily occurs due to roadside blasts or bombs.
Time to treatment is a significant hurdle to reducing the severity of TBI-MBI on the battlefield. Roughly 50% of military severe TBI survivors suffer major long-term impairments. The ideal medication would be to rapidly provide oxygen-rich fluid to the damaged tissue. It must be portable, stable at room temperature, and easy to use quickly after a TBI-MBI occurs. We believe Oxycyte has these ideal characteristics. As such, we expect significant U.S. military interest in Oxycyte should the STOP-TBI program offer positive data.
Beside the potential army use in TBI and MBI, we note the U.S. Navy has been looking at Oxycyte for the potential treatment indications as well. Oxygen Bio has signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Research Center (NMRC) to conduct preclinical trials using swine models to assess the safety and efficacy of Oxycyte for decompression sickness, spinal cord injury due to decompression sickness (DCS) and hemorrhagic shock. An investigation new drug application (IND) for the treatment of decompression sickness is expected later in 2010.
In June 2010, the U.S. Navy release data from a study demonstrating decreased mortality in porcine animal models that were given an intravenous dose of Oxycyte emulsion after the onset of DCS. These results showed a statistically significant decrease in mortality compared with the control group that did not receive Oxycyte. The data was published in the June issue of Aviation Space and Environmental Medicine.
The data show a 72% 24-hour survival for the Oxycyte group vs. 45% for the control (p<0.05). Functional recovery as measured by the Tarlov Scale was also higher for the Oxycyte test group, 52% vs. 28%, compared to the control. The authors of the paper are Drs. Richard T. Mahon, Tomas T. Watanabe and Charles R. Auker and Madison C. Wilson, all of the Undersea Medicine Department at the U.S. Naval Medical Research Center. Their work was funded by the Office of Naval Research.
The NMRC plans to conduct studies in spinal cord injury and hemorrhagic shock next. The protocol for the spinal cord injury trial will measure safety and efficacy of Oxycyte in conjunction with recompression therapy. The hemorrhagic shock protocol will look at using Oxycyte for preservation of systemic oxygenation in large porcine models.
Approval for use of Oxycyte by the U.S. Navy based on animal-rule data could come by 2012. This could be a significant opportunity for Oxygen Bio based on the characteristics of the drug and the potential for broad-scale deployment on U.S. or NATO submarines.
In a bullish scenario, we envision the U.S. Navy purchasing Oxycyte for its 250 – 300 submarines with an estimated 100 to 120 doses per ship. The same characteristics that make Oxycyte attractive to the U.S. Army – portable, stable at room temp, easy to use – also fit well within what the U.S. Navy would be looking for on a disabled vessel.
We believe Oxycyte has the ideal characteristics for several potential applications in the field of combat or during active service. Oxycyte is a proprietary perfluorocarbon (PFC) therapeutics oxygen carrier is designed to enhance oxygen delivery to damaged tissue. When used as an intravenous emulsion, Oxycyte can carry as much as 4x the amount of oxygen as a normal red blood cell (RBC) despite being nearly 1/50th the size.
Oxycyte has 50x greater O2 solubility and diffusibility than RBCs and can move through the circulatory system at rates up to 2x the speed of hemoglobin. Thus, Oxycyte is highly efficient for transporting oxygen to tissues and carrying carbon dioxide (CO2) to the lungs for disposal.
The product is not a blood substitute because it does not include white blood cells, antibodies or plasma. There are no supply issues and no disease transmission / typing or cross-matching limitations. It also has a shelf-life far greater than the 42 days for human donated blood.
Oxygen Bio expects to market Oxycyte with a 12 to 18 month shelf-life, although in theory the product could last much longer given its chemically and thermally stable structure.
OXYGEN BIOTHERAPEUTICS INC (OXBT): Read the Full Research Report
Zacks Investment Research
ADVERTISEMENT
Zacks Investment Research
It looks like Oxbt and its enormous potential is still alive..., hope we will get some information about the first cohort soon, at least how many survived or a massive decrease in mortality, etc ?? I like the approach of adjusting the protocol in favor of milder TBI, which will open an even bigger field of potential and also our sports heros can be treated soon...
Oxygen Biotherapeutics TBI Study to be Offered to Injured Israeli Soldiers
Israel's Medical Corps Determines Soldiers Do Not Need Prior Approval to Participate
DURHAM, N.C., Sep 7, 2010 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT), a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced that Israeli soldiers who suffer severe traumatic brain injury (TBI) can be enrolled in the company's Phase II-b STOP-TBI trials at clinical sites in Israel. In view of this development, the company announced that it seeks to amend the existing study protocol to broaden the qualified patient enrollment population to include moderate/mild TBI patients. The company expects to reconvene enrollment in its second cohort after the required regulatory adjustments have been approved. The result of these two actions should increase the patient population that qualifies for enrollment in the study.
"Today, traumatic brain injury is one of the most common impairments faced by our military personnel all over the world. Land mines, rocket-propelled grenades and improvised explosive devices are now the most common tools of war. When they strike, body armor and helmets may protect, but what is not as easily recognizable is the damage these weapons are doing to service members' brains. Sometimes it is an obvious injury; other times it is mild to moderate. Therefore, we are considering modifying our study protocol to include moderate/mild TBI cases. As a company, we believe it is our duty to help these men and women who otherwise have little to no solution when afflicted with a brain injury. We are pleased that the Israeli Medical Corps will allow soldiers to participate," said Chris Stern, Chairman and Chief Executive Officer of Oxygen Biotherapeutics.
Currently, Oxygen Biotherapeutics has a Phase II-b clinical study underway to determine the safety and efficacy of using Oxycyte intravenously to treat severe TBI patients. These studies are being conducted at clinical sites in Switzerland and Israel with plans to expand into India. The company expects to allocate a substantial portion of its financial and business resources over the next few years to testing Oxycyte and advancing this product to regulatory approval for use in one or more medical applications.
Oxycyte oxygen carrier is a perfluorocarbon emulsified with water and a surfactant, which is provided to the patient intravenously. The physical properties of Oxycyte enable it to gather oxygen from the lungs and transport the oxygen through the body releasing it along the way. Increased oxygenation is vital for the recovery of TBI patients. TBI is a non-degenerative, non-congenital insult to the brain from an external mechanical force, possibly leading to permanent or temporary impairment of cognitive, physical, and psychosocial functions, with an associated diminished or altered state of consciousness.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The Company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product called Oxycyte(R) that is being formulated for both intravenous and topical delivery for conditions including but not limited to traumatic brain injury, decompression sickness and topical wounds. This same PFC is included in the Company's full line of personal skin care products. More information is available at www.oxybiomed.com.
The Oxygen Biotherapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7277
is this good or bad ? it looks like the CEO seems to be smart enough to trigger a bonus for himself, knowing that he will benefit of those warrants only if the stock price will rise above 3.75 USD. So will he be smart enough to help the share price which will help him ? I think in the end we (longs) are all in the same boat , we only benefit if the stock will go up, including management and board. It comes down to capability. If he fails to deliver soon he is done in this industry anyway, so I might be naive but deep down I hope the CEO has the same interest - a higher share price quite soon. Is the management capable ? we will see. I guess this year is the make or break , this company needs a license deal which would bring back some confidence and it is the proof of concept and "reality check" for the potential of the core product (oxygen delivery - PFC)
DURHAM, N.C., May 19, 2010 (GlobeNewswire via COMTEX) --Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) announced today that the Company has formalized working relationships with an international cosmetic company and a site monitoring company.
The cosmetic company has agreed to evaluate the patented technology underlying the Company's non-prescription topical beauty care products for potential use in a product line targeted for retail-based channels of trade, including mass market retailers.
Does anyone know anything about this ? time is passing and no result... again ?!?!
What is happening with the biosensor ?
The chairman mentioned in one of his letters that there will be no communication about the TBI trial until it is finished. From this side we can not expect anything coming, positive nor negative.
Funds are probably running out by the end of this year, without a license deal-upfront payment or big sales from Dermacyte ( later is not likely to happen before end of next year if at all), we might experience again a catastrophic funding event. Did the management deliver anything since they received 5 Million USD in May 2010 ? Is the management capable to deliver ? according to blimps - not, according to no news coming - not really. What does it need and how much more time do they need to perform ? many questions, no answers and more frustration, dear management , it is time to surprise the shareholders with positive news and facts.
12 Million turnover with one and the first product, production cost about 5-10% ( cosmetic average ?).
Do you have any idea what a license deal would be worth in such a situation ? if one product works, we could believe that many other indications are as promising as Dermacyte, if not more successful and clinical indications are still alive and also potential money earners. A company with such a turnover, a "full, very promising pipeline" and a huge market potential does cost more than 230 Million USD. But that is just my opinion and not binding to any future stock price, many things can happen. If this is funny for you , I hope it could put a smile on your face, you need it.
very interesting closing trades, again, it looks like it could potentially confirm the theory posted recently about some people having a huge interest that this stock is not getting any momentum. I think it would be worth looking into this "manipulation" a bit deeper.
back in April I thought Oxbt would not need a capital increase, I assumed ( and I know you should never assume, as it makes an "a.." out of "u" and "me") the peer fund or money from warrant exercise or an other form of financing would come but never thought new shares at such low levels would be issued. I was wrong. Ever since we have a very negative trend and this is very hard to digest. I think the terms and conditions of that "not so popular" financing caused the negativity. Before this company had many supporters, not any more. Share holders feel being left out, betrayed, neglected a huge variety of possible words could be added here and some not so nice ones as well. Now we have a "confidence crisis" with management and board, this might also be a reason why most share holders give in , sell or/and do nothing but complain. Management has to restore trust and the only way they can do that is probably with a license deal with big numbers, - proof of concept. If the deal is good for Oxbt, then this deadly downward spiral could turn very fast. Most of share holders got in when it was only about TBI etc., now it looks more like Oxbt will try to harvest so called "low hanging fruits" with topical indications, several of them. I believe this has a very promising potential which is much bigger than TBI and could bring revenues much earlier. Topical indications, especially wound healing is very big and it looks like nobody is taking this into consideration nor calculation of Oxbt's market cap. I think management didn't do everything wrong, but the terms of recent financing, the salary increases for certain people in the company, the "family issue" within the company, the way of communication etc , is not ideal, to say the least.
I believe the potential of topical products is huge and therefore I stay in but management is playing a crucial role here and if they do not deliver soon ......? Are the people in the driver seat capable of closing a good license deal ? I don't know, we will see. But if this deal would come this stock would skyrocket above 10 USD. When this will happen - I don't know,
Can it happen ? I think yes. I am using the product and it works, so from this side it is possible.
I heard that Oxbt has a few thousand of individual share holders. If they all would use and buy the product (which works), the Company would have huge sales numbers and profit. So it is also in our hands to make this a success. With only 10'000 customers and each would buy products worth of 100 USD per month ?! this company would be traded much higher than 10 USD per share.
Clinical indications are important but will not bring any revenues to the company for years. Data will come and hopefully they will be as good as the results of phase IIa , for which the Principal Investigator Dr. Ross Bullock got the Olivecrona Award ( Neurosurgery) in Stockholm in 2007.
(I am going with Bullock and not Spiess.)
"President-elect, National Neurotrauma Society, 2010-2011
Chair, Department of Defense Congressionally mandated Advisory Board for Traumatic Brain Injury, 2009.
Olivecrona award for research in Traumatic Brain Injury, 2007 (Karolinska Institute, Stockholm)
Safety monitoring board, Traumatic Brain Injury in Latin America: Lifespan analysis NIH NINDS .
Congress of Neurological Surgeons.
Oxbt can only look for a partner and license it out asap (early stage) but data has to be convincing and complete, this takes time and money.
Overall I am convinced that this company is massively undervalued and "one day" it will go up like DNDN for example.
This year christmas might come earlier !
Maybe it sounds to good to be true, everyone should do their DD before investing, but what I do not understand is the motivation of some people (not being invested in this company) bashing this stock every single chance they get. What a sad life..., or are they "mother teresa" and want to save all investors, don't think so....
it is obvious that some people or group have the biggest interest that this stock is not going up and getting momentum. Unfortunately for all "longs" this is quite frustrating. Who could have such an interest ? Maybe "shorts", maybe investors who are fed up with the situation, sold before and with the rest of their holdings they try to damage the company? not very likely, or maybe warrant holders who have warrants of which the exercise price will be adjusted would there be another round of financing at a lower price then their exercise price ? I might be wrong but don't have the 800'000 warrants which came along with the last financing, such a clause ? I hope I am wrong. I also hope this is a conspiracy theory. We saw in the last few weeks clever placed selling orders and/or limited selling of shares around 2.90 USD (before also at higher prices from 4.40 down to 2.5) and an immediate drop at the end of the trading session or a few minutes after a news has been released. A psychologist mentioned once : "If you want to destroy a positive momentum in a stock price just sell on news, good or bad news just sell and stay strong with selling. If you succeed a few times, "long" investors are backing off and take a wait and see stance". That potential group has over 1 Million shares to play with, by doing so ( selling around cost or higher) they reduce their risk and with the potentially adjusted exercise price of their 5 year maturity warrants at a lower level this might be a "free lunch" for them. Can we blame them ? I think not, they just try to make as much money as they can by reducing their risk and taking advantage of their clause. Who wouldn't do the same thing in their position in the current circumstances ? If the price skyrockets they win anyway and make a profit with their shares and warrant position, but if Oxbt fails ? at least they sold a decent part of their "core holdings" early enough. I think this is called risk management, isn't it ?
and of course "bashing" never helped a stock moving up...
It is time for a big surprise....,
you wrote ; Along with this move is the move of all Vcure studies. OXBT no longer has any affiliation with VCURES. It is now Sanguines product they are testing for the Navy, etc .
"the lying SOB" has posted in the latest letter "...Specifically, this week we were pleased to learn of the recent PFC research activity being undertaken at Virginia Commonwealth University that involves the use of the PFC PHER-O2for preclinical trials. An announcement from their PFC supplier said the VCU preclinical work will be focused on traumatic brain injury, traumatic spinal cord injury, organ preservation and other areas covered by our licensing agreement with VCU. [color=red][/color]
Why is this positive for OXBT and shareholders? Our license with VCU provides us with rights to
discoveries that lead to commercial PFC-based diagnostics and therapeutic products for humans and
animals, particularly in the fields of traumatic brain injury, traumatic spinal cord injury, stroke, organ
preservation and intravenous enhanced oxygen and many other indications. If they succeed, patients
succeed…and we succeed.
So is it now good for share holders or bad, "game over" style ?! Doesn't this letter indicate that Oxbt is covered for such incidents ?
I would imagine that Spiess still has a binding agreement of some sort with Oxbt (as a former board member of the company), I am sure Oxbt covered themselves in a way that Spiess can not harm the company or the IP, am I wrong ?
Please also let us know about the "lying" part from Chris Stern, many thanks for bringing light into this matter....
many things might be the way you say but Stern's monthly share compensation and "parachute" is split adjusted, the numbers you mentioned divided by 15
not even "Zacks" could foresee such a capital transaction (May 2010) . Such an unbelievable management and board decision which did cost almost all share holders trust in the management.
But this is only short term and sure some people think that the "leaders" made this decision in the best interest of the company in the long term......., is there a single soul left who believes in the capability of "those leaders"?
I really wonder who those buyers were at 2.9 from the last capital transaction ? if they were "good ones", they would have been disclosed before, if "not so good ones" then not. We have to wait a few more days and hopefully we can read that information in the Q . But it looks like that the stock will not go up until the market has absorbed the 1.7 Million shares issued at 2.9 because "they" are loading off ! again what a disgrace of financial transaction that was, some people in that management have not really succeeded and performed in their duty " in the best interest of share holder value ". Who wants new leaders! Because the product works but this management can't make it happen, which it proves all the time.
Abstract:
Mahon RT, Watanabee TT, Wilson MC, Auker CR. Intravenous perfluorocarbon after onset of decompression sickness decreases mortality in 20-kg swine. Aviat Space Environ Med 2010; 81:555-9.
Introduction: Decompression sickness (DCS) occurs when bubbles form due to pressure decreases with severity ranging from trivial to fatal. Standard treatment requires a hyperbaric chamber, not likely to be available at remote sites or during a disabled submarine escape or rescue. Alternative (non-recompressive) treatments are needed. Intravenous administration of emulsified perfluorocarbons (PFCs) enhances oxygen delivery to, and inert gas removal from, tissues. Swine studies show PFCs administered with supplemental oxygen before symptom onset can decrease DCS incidence. We used a swine model to test whether PFC plus supplemental oxygen could improve outcome when infused after DCS symptom onset. Methods: After rapid decompression from 31 min at 200 fsw (7.06 ATA) animals were observed for signs of DCS. Upon DCS onset animals received 100% O2 and were randomized to receive either saline or PFC. Oxygen administration was continued for 1 h and the primary outcomes of mortality and/or abnormal gait were noted 24 h after surfacing. Results: PFC significantly improved survival, with 18/25 (72%) PFC treated animals and 13/29 (45%) saline treated animals alive at 24 h post-exposure. Objective measures of stance/gait trended toward improvement; spinal cord lesions correlated with severity of stance/gait abnormalities. Conclusion: PFC administered after DCS onset improved survival in this 20-kg swine model. Further study into the mechanisms of benefit and delayed DCS therapy are warranted.
Apparently there is a study out from Navy results with PFC. In Europe this news or link has been released but I can not find anything in the US ?? - It is written in French -
30-06-2010 07:30 Oxygen Biotherapeutics: bons résultats d'étude pré-clinique avec le PFCE
Name Letzter Veränderung
OXYGEN BIOTHERAPEUTICS ORD 3.02
0.03 (1.00 %)
Zurich (awp) - La société de biotechnologie américaine Oxygen Biotherapeutics, cotée depuis mardi le 29 juin 2010 sur SIX Swiss Exchange, a obtenu de bons résultats avec l'émulsion d'oxycyte perfluorée (PFCE). Une étude de la US Navy sur des porcs a montré une diminution de la mortalité dans les accidents de décompression, lorsque les sujets ont reçu une dose de PFCE en intraveineuse.
Les résultats de l'étude font apparaître un net recul statistique de la mortalité par rapport au groupe de comparaison n'ayant pas reçu de PFCE.
Les données ont été publiées dans l'édition de juin de la revue "Aviation Space and Environmental Medicine". L'étude a été financée par l'Office of Naval Research américain.
long time no comments from many of the posters including myself as we are probably all gob smacked about the PPS and the company development or lack luster disorientation. I actually do not have words for the recent actions taken by management especially the terms of the financing, hiring sales staff and trying to attract regional sales license ?! It does not add up and I am very confused to the point that I can not trust Mr. Stern anymore. Why is the board not acting upon such unbelievable mismanagement ? Where is the Vatea fund in this game ? Let's get an open discussion started , forget about emotions, most of us have the same goal , what should be done ? Is the present board and management the right one to make this company a success ?
technically a very good move down to 4.72, to the point to close the "gap", very good news chart wise. The "freakish" volume and price spike was impressive but not substantial, and the price decline is for many long's frustrating but check out other Biotech Nasdaq listed stock, which moved very similar on news recently, MRNA and BTIM. At least a sign that this stock is on the radar screen of many Investors who are willing to put money into that stock on good news. The overall risk to invest in such a company with that"low mkt cap" is calculable, given a vast range of potential income sources, huge scientific research data, strong patents and various income "pillars", financed, clear strategy and soon revenues. But of course "it" can't see because "it" doesn't want to see nor believe nor imagine. Absolutely correct : Oxbt's topical application is not a threat to Cosmetic Giants, those products are not in big competition with anything out there because there is nothing similar to this product on PFC basis, so it is something more than a threat , it is a "new" product which can deliver oxygen to the skin more effective than anything else on the market and a potential "block buster", which is never a bad thing to have in the pipe line. It is possible that some of the companies will move fast to secure a distribution deal with Oxbt, but of course "DD" is the key and that can take up to six month or more depending on the analysis and depth of "DD" and strategy. Sure TBI data is important but also every other data form "IV" indication is important and will add value to the company. Oxbt needs something "substantial" and then it will fly. Prove of concept is here, now credibility is needed, which will come. Oxbt is a clear buy at this level, I am convinced of all the products Oxbt is developing, based on Oxycyte.
I hang in there and wait for the big $$$, even if it takes some more time, it doesn't matter, it will happen and maybe sooner than we think.
technically a very good move down to 4.72, to the point to close the "gap", very good news chart wise. The "freakish" volume and price spike was impressive but not substantial, and the price decline is for many long's frustrating but check out other Biotech Nasdaq listed stock, which moved very similar on news recently, MRNA and BTIM. At least a sign that this stock is on the radar screen of many Investors who are willing to put money into that stock on good news. The overall risk to invest in such a company with that"low mkt cap" is calculable, given a vast range of potential income sources, huge scientific research data, strong patents and various income "pillars", financed, clear strategy and soon revenues. But of course "it" can't see because "it" doesn't want to see nor believe nor imagine. Absolutely correct : Oxbt's topical application is not a threat to Cosmetic Giants, those products are not in big competition with anything out there because there is nothing similar to this product on PFC basis, so it is something more than a threat , it is a "new" product which can deliver oxygen to the skin more effective than anything else on the market and a potential "block buster", which is never a bad thing to have in the pipe line. It is possible that some of the companies will move fast to secure a distribution deal with Oxbt, but of course "DD" is the key and that can take up to six month or more depending on the analysis and depth of "DD" and strategy. Sure TBI data is important but also every other data form "IV" indication is important and will add value to the company. Oxbt needs something "substantial" and then it will fly. Prove of concept is here, now credibility is needed, which will come. Oxbt is a clear buy at this level, I am convinced of all the products Oxbt is developing, based on Oxycyte.
I hang in there and wait for the big $$$, even if it takes some more time, it doesn't matter, it will happen and maybe sooner than we think.
some see the glass half full some half empty, one very happy bunny sees it always empty, ignores moves, volume, news, development but this at least very constantly, must be a bright shinning world "it" is living in. It would probably also comment on a intraday low when the stock is at 20 USD pps, good that we all can decide for ourselves if we want to read and believe things.
I wouldn't be surprised when Oxbt would come up with some other "good news" down the line as I hope they haven't only developed Dermacyte's formula in the last 4 months. The good thing about yesterdays record volume, it confirms that still many investors are willing to enter the stock at this level, probably because it is promising. Until today the stock price has not encounterned any possible revenues and potential license deals for topical application and not even a big percentage of the TBI potential when successful is in the pps. TBI on its own has a big double digit billion potential per year,so have the topicals, and many many indications more. Even at 15 USD pps the mkt cap is "only" just over 300 Million USD, compared to the multi billion markets in every single application of Oxycyte this company is not overvalued at all. And looking at the competitors, ups there aren't any, the probablility of getting a nice piece of the cake is rather big. Due to some "big tickets" it looks like some "big fish" started to buy Oxbt and it was a selling chance for all those who do not believe in the company. I am very glad for all those who could get out and sell and please stay away form this "terrible company". Once sold doesn't mean you can't get back in, it is only about timing, "play or stay", the longs will be rewarded and "no big gain without big pain".
nice to be wrong :) the shorts lost this time and "our friend's" incentive payer burnt their fingers, shorts were covered in the opening stage and again after 40 minutes, but some shorts were reopened at 6.30 later in the session. "our friend" did what he could do to create panic and "talk it down" but that didn't help his people this time, but they won about 7 times already, so fair enough , some loose some win. Fundamentally the potential in topical applications is actually bigger than TBI and brings much earlier revenues.
Of course we all want to see good data from TBI, but a license deal with a big cosmetic company is needed first to get credibility and with further development of the product it could be a real winner. 10 USD pps is "only" a mkt cap of 210 Million USD, if the above will materialize this could be a 50 USD stock (actually much more) in a couple of years. So it doesn't really matter in the long term if you bought at 4.6 or 5.8 or 7 , people start realizing that this could be a potential winner. Todays PR was written in a different style, good style, thanks God. What will happen with the pps when institutional start buying later this year ? Let's hope this is the turnaround in momentum.